PeptiStrong® (Fava Bean Peptide Hydrolysate)

Vicia faba
Evidence Level
Limited
2 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

PeptiStrong® (Nuritas) is a fava bean (Vicia faba) protein hydrolysate whose peptide sequences were identified using a machine-learning screening platform. In laboratory and animal work the peptides activate the mTORC1 pathway and suppress myostatin. Human evidence comes from three small randomized trials: one independent trial found the peptide matched milk protein for preserving muscle size and raised muscle protein synthesis during recovery from immobilization, while two manufacturer-funded trials reported improved strength recovery, reduced fatigue, and gains in strength and muscular endurance with resistance training. The effects are modest, the positive strength and endurance findings have not been independently replicated, and ordinary dietary protein and whey have far more evidence behind them.

Studied Dose 2.4 g/day in the Nuritas strength-recovery and strength/endurance trials. The independent Maastricht trial used a higher dose, 20 g/day (10 g twice daily).
Active Compound Fava bean (Vicia faba) protein hydrolysate / pro-anabolic peptide network (PeptiStrong, Nuritas); 2,400 mg/day dose.

Benefits

Muscle protein synthesis and recovery acceleration

In an independent trial, the peptide network raised muscle protein synthesis rates during recovery from limb immobilization, and a manufacturer-funded trial reported faster strength recovery and reduced fatigue after damaging exercise. The peptides activate the mTORC1 pathway and lower plasma myostatin. The recovery effects are modest and the trials are small, so this is promising rather than established.

Strength and muscle performance

Two manufacturer-funded randomized trials reported improved strength recovery and greater leg-strength gains with resistance training versus placebo. The independent trial, by contrast, found the peptide no better than milk protein for preserving muscle size. The positive strength findings are modest, come from small trials, and have not been independently replicated.

Protein utilization (not directly measured)

An independent trial found higher muscle protein synthesis rates during recovery from immobilization with the peptide than with milk protein. Claims that it lets the body extract more muscle-building value from ordinary protein intake go beyond what has been directly measured, and a separate trial of whole fava bean protein found no increase in muscle protein synthesis.

Muscular endurance

One manufacturer-funded trial (72 adults, 56 days of resistance training) reported greater muscular endurance, measured as repetitions to exhaustion, versus placebo. This is resistance-exercise endurance rather than aerobic capacity, the trial was funded by the maker, and the finding has not been independently replicated.

Mechanism of action

1

AI-identified peptide mTORC1 activation and myostatin inhibition

Nuritas' Magnifier AI platform analyzed thousands of fava bean protein sequences against proteomics databases to identify peptide sequences with predicted mTORC1 activating and myostatin-binding properties. The identified peptides activate mTORC1/p70S6K signaling (triggering muscle protein synthesis initiation) while simultaneously binding and partially blocking myostatin — the TGF-β family member that limits muscle growth. This dual mechanism is proposed to support the anabolic response to exercise, but it has not been tested head to head against leucine or EAA supplementation in people.

Clinical trials

1
PeptiStrong® for Muscle Recovery — RCT
PubMed

Randomized, double-blind, placebo-controlled trial of PeptiStrong® (2,400 mg/day fava bean peptides) effects on recovery from exercise-induced muscle damage. Outcomes: CK, range of motion, strength recovery. (Kerr 2023, Nutrients)

Trained adults post-exercise.

PeptiStrong® accelerated recovery from exercise-induced muscle damage, reduced CK elevation, improved range of motion vs placebo. Industry-funded (Nuritas). Effect sizes modest. Note: PeptiStrong® was 'discovered' using AI-driven peptide screening from fava beans — novel discovery approach.

2
PeptiStrong® for Muscle Protein Synthesis — RCT
PubMed

Independent randomized controlled trial (Maastricht University) in 30 young men comparing the fava bean peptide network (NPN_1/PeptiStrong, 10 g twice daily) with milk protein during 7 days of leg immobilization and 14 days of remobilization. Outcomes: quadriceps size and muscle protein synthesis. (2023, J Nutr)

Active adults.

The peptide network did not differ from milk protein for the primary outcome, quadriceps size, during immobilization or remobilization. Muscle protein synthesis rates during remobilization were higher with the peptide than with milk protein (a secondary outcome). This is non-inferiority to ordinary protein, not superiority. A separate trial of whole fava bean protein found no rise in muscle protein synthesis. Whey and milk protein have decades of stronger evidence.

Side effects and drug interactions

Common Potential side effects

Excellent safety profile — fava bean food-derived ingredient
Fava bean (broad bean) allergy — rare; discontinue if reaction
G6PD deficiency — fava beans contraindicated in G6PD-deficient individuals (favism risk)

Important Drug interactions

mTOR inhibitors (rapamycin, everolimus) — mTOR activation may oppose; consult physician in transplant patients
MAO inhibitors — fava beans contain L-DOPA precursors; avoid in patients on MAO inhibitors
No significant interactions at 2.4g/day for healthy individuals

Frequently asked questions about PeptiStrong® (Fava Bean Peptide Hydrolysate)

What is PeptiStrong?

PeptiStrong® (Nuritas) is a fava bean (Vicia faba) protein hydrolysate whose peptide sequences were identified using a machine-learning screening platform. In laboratory and animal work the peptides activate the mTORC1 pathway and suppress myostatin.

What is PeptiStrong used for?

PeptiStrong is researched primarily for Athletic Performance and Muscle & Recovery. In an independent trial, the peptide network raised muscle protein synthesis rates during recovery from limb immobilization, and a manufacturer-funded trial reported faster strength recovery and reduced fatigue after damaging exercise.

What is the recommended dosage of PeptiStrong?

The clinically studied dose is 2.4 g/day in the Nuritas strength-recovery and strength/endurance trials. The independent Maastricht trial used a higher dose, 20 g/day (10 g twice daily). Always follow the product label and check with a healthcare provider for personal advice.

Is PeptiStrong safe, and does it have side effects?

For most healthy adults, PeptiStrong is well tolerated at studied doses. Reported effects can include: Excellent safety profile — fava bean food-derived ingredient Fava bean (broad bean) allergy — rare; discontinue if reaction It may also interact with some medications. PeptiStrong is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does PeptiStrong interact with any medications?

Possible interactions include: mTOR inhibitors (rapamycin, everolimus) — mTOR activation may oppose; consult physician in transplant patients MAO inhibitors — fava beans contain L-DOPA precursors; avoid in patients on MAO inhibitors If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for PeptiStrong?

NutraSmarts rates the evidence for PeptiStrong as Limited (2 out of 5). It is backed by 2 clinical trials and 5 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(5 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Weijzen MEG, Holwerda AM, Jetten GHJ, Houben LHP, Kerr A, Davis H, et al. Vicia faba Peptide Network Supplementation Does Not Differ From Milk Protein in Modulating Changes in Muscle Size During Short-Term Immobilization and Subsequent Remobilization, but Increases Muscle Protein Synthesis Rates During Remobilization in Healthy Young Men. The Journal of Nutrition. 2023;153(6):1718-1729. doi: 10.1016/j.tjnut.2023.01.014.PubMedUsed to support: Independent (Maastricht) RCT in 30 young men showing the fava-bean peptide network (NPN_1/PeptiStrong) matched milk protein for muscle-size changes during immobilization/remobilization and produced higher muscle protein synthesis rates during recovery. Strongest PeptiStrong human evidence, but it is a single small trial and the ingredient is very new.
  2. Kerr A, Hart L, Davis H, Wall A, Lacey S, Franklyn-Miller A, et al. Improved Strength Recovery and Reduced Fatigue with Suppressed Plasma Myostatin Following Supplementation of a Vicia faba Hydrolysate, in a Healthy Male Population. Nutrients. 2023;15(4):986. doi: 10.3390/nu15040986.PubMedUsed to support: Randomized, double-blind, placebo-controlled trial reporting the Vicia faba hydrolysate (PeptiStrong/NPN_1) improved strength recovery, reduced fatigue, and suppressed plasma myostatin. Supports the muscle-recovery claim; small, manufacturer (Nuritas)-funded, and preliminary.
  3. Corrochano AR, Cal R, Kennedy K, Wall A, Murphy N, Trajkovic S, et al. Characterising the efficacy and bioavailability of bioactive peptides identified for attenuating muscle atrophy within a Vicia faba-derived functional ingredient. Current Research in Food Science. 2021;4:224-232. doi: 10.1016/j.crfs.2021.03.008.PubMedUsed to support: Mechanistic paper identifying the bioactive peptides within NPN_1/PeptiStrong, showing they increase protein synthesis, reduce atrophy-gene expression and TNF-alpha in vitro, and survive simulated digestion. Provides the mechanistic rationale, but it is preclinical (cell/in vitro plus murine) and manufacturer (Nuritas)-generated; only a few PeptiStrong-specific papers exist to date.
  4. Davies RW, Kozior M, Lynch AE, Bass JJ, Atherton PJ, Smith K, Jakeman PM. The Effect of Fava Bean (Vicia faba L.) Protein Ingestion on Myofibrillar Protein Synthesis at Rest and after Resistance Exercise in Healthy, Young Men and Women: A Randomised Control Trial. Nutrients. 2022;14(18):3688. doi: 10.3390/nu14183688.PubMedUsed to support: Independent RCT (n=16) of whole fava bean protein (0.33 g/kg), not the branded hydrolysate; ingestion did not raise resting (p=0.409) or post-exercise (p=0.732) myofibrillar protein synthesis versus control. Null.
  5. Mohan NM, Khaldi N, Keogh B, Franklyn Miller A. Randomised, double-blind, placebo-controlled study to evaluate the effect on human strength and endurance after resistance training and supplementation of Vicia faba protein hydrolysate compared with placebo. BMJ Nutrition, Prevention & Health. 2025;8(1):e001050. doi: 10.1136/bmjnph-2024-001050.PubMedUsed to support: Nuritas-funded RCT (n=72, 56 days resistance training) reporting greater leg strength (p=0.045/0.05) and greater muscular endurance (repetitions to exhaustion, +21.6% vs placebo, p=0.022).